Navigation Links
ImaginAb, Inc. Announces Formation of Singapore Subsidiary, ImaginAb Molecular Imaging Pte Ltd.
Date:9/6/2011

LOS ANGELES and SINGAPORE, Sept. 6, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the establishment of a wholly owned Singapore-based subsidiary, ImaginAb Molecular Imaging Pte Ltd (IMI). IMI is the first step in the company's international expansion and marks a significant increase in research capability for the organization. IMI will be established to provide GLP pre-clinical molecular imaging services to both the US parent company and select biopharma partnerships, including optical imaging and positron emission tomography (PET) services.

Christian P. Behrenbruch, Ph.D, ImaginAb's CEO, commented, "Singapore has tremendous resources and facilities of interest to ImaginAb. We already have a close dialog with several A*Star Research Institutes (RIs) and a formalized collaboration with Sir David Lane's lab at the Institute of Molecular Biology (IMB)." The establishment of IMI will strengthen the possibility of further collaborations with A*Star, university labs and several global pharmaceutical companies who have established translational medicine units in Singapore.

"Establishing a significant research footprint in Singapore has been a straightforward process, greatly facilitated by the ease of working with A*Star, EDB and other government stakeholders who are committed to bringing highly innovative US companies to a growing and dynamic biotech cluster," commented Dr. Behrenbruch. "We are impressed with the quality of industry-accessible core resources and the international talent base in Singapore. We also expect ImaginAb's footprint in Singapore will also enable the company to better service a rapidly growing client base in Korea, Japan and China."

About ImaginAb, Inc.

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Anna Wu
http://www.profnetconnect.com/anna_wu


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology
2. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
3. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
4. Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
5. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
6. Genprex Announces New Branding
7. BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026
8. BioInformatics LLC Announces the Life Science Industry Awards on November 15, 2011 in Washington, DC
9. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
10. BD Biosciences Announces Winners of Research Grant Program
11. SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- Novan, Inc. today announced that Director Robert A. Ingram ... Novan. In addition, Robert Keegan has been appointed to ... . --> North Carolina . ... total of $32.8 million of net proceeds in a private Mezzanine ... throughout the Research Triangle area of North Carolina ...
(Date:2/8/2016)... ... ... Information Management Services ( IMS ) is pleased to announce a major ... foundation and is so significant it was endowed with a new name, BSI Engage. ... results, a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, ... present information about the company,s programs at the BIOCEO conference today ... City . --> --> ... Registered attendees can request a one on one meeting through the conference ... --> New York City . --> ...
(Date:2/8/2016)... 8, 2016 --> ... the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today ... Chlamydia trachomatis (CT) test to be launched on the Company,s ... (98/79/EC), the CT test is now cleared for sale within ... The launch of the io® CT test signals a ...
Breaking Biology Technology:
(Date:1/21/2016)... , January 21, 2016 ... a new market research report "Emotion Detection and Recognition ... Software Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020", published by MarketsandMarkets, the ... to reach USD 22.65 Billion by 2020, at ...
(Date:1/20/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce the attainment of ... the result of the company,s laser focus on (and ... , it,s comprehensive, easy-to-use and highly affordable cloud-based technology ... Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
Breaking Biology News(10 mins):